FAQ: Bluejay Diagnostics Inc. (NASDAQ: BJDX) Secures $3.7M in Warrant Inducement Transaction

What is Bluejay Diagnostics Inc.?

Bluejay Diagnostics Inc. is a medical technology company focused on developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, with its first product candidate being an IL-6 Test for sepsis.

How much did Bluejay Diagnostics Inc. secure in the warrant inducement transaction?

Bluejay Diagnostics Inc. secured approximately $3.7 million in gross proceeds from the warrant inducement transaction.

What was the exercise price per share in the warrant inducement transaction?

The exercise price per share was reduced to $3.42 in the warrant inducement transaction.

Who acted as the exclusive financial advisor for the transaction?

Aegis Capital Corp. acted as the exclusive financial advisor for the transaction.

What is the Symphony System?

The Symphony System is Bluejay’s cost-effective, rapid, near-patient testing system designed for sepsis triage and monitoring of disease progression, aiming to provide accurate results in approximately 20 minutes.

Where can I find more information about Bluejay Diagnostics Inc.?

More information about Bluejay Diagnostics Inc. is available at www.Bluejaydx.com.

What are the implications of this transaction for Bluejay Diagnostics Inc.?

This transaction provides Bluejay Diagnostics Inc. with additional funding to support its development of rapid diagnostics, potentially accelerating its efforts to improve patient outcomes in critical care settings.

Who were the legal advisors involved in the transaction?

Hogan Lovells US LLP acted as counsel to Bluejay Diagnostics Inc., and Kaufman & Canoles, P.C. served as counsel to Aegis Capital Corp.

What is the significance of the IL-6 Test for sepsis?

The IL-6 Test for sepsis is significant as it is designed to provide accurate, reliable results in approximately 20 minutes, aiding medical professionals in making earlier and better triage/treatment decisions.